Chemoprevention of 7,12-dimethylbenz[a]anthracene (DMBA)-induced oral carcinogenesis in hamster cheek pouch by topical application of a dual inhibitor of epidermal growth factor receptor (EGFR) and ErbB2 tyrosine kinases

Oral Oncology

Volumn 44, Issue 7, 2008, Pages 652-657

  Sun, Zheng ^a,b   Sood, Sandeep ^c   Li, Ning ^d   Yang, Peiying ^e   Newman, Robert A ^e   Yang, Chung S ^c   Chen, Xiaoxin ^a,c  

^a NORTH CAROLINA CENTRAL UNIVERSITY   (United States)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c RUTGERS UNIVERSITY   (United States)

^d CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

DMBA; EGFR; GW2974; Oral cancer

Indexed keywords

ARACHIDONIC ACID; DIMETHYLBENZ[A]ANTHRACENE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GW 2974; HYDROXYICOSATETRAENOIC ACID; LEUKOTRIENE B4; PROSTAGLANDIN E2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARACHIDONIC ACID METABOLISM; ARTICLE; CELL PROLIFERATION; CHEEK POUCH; CHEMICAL CARCINOGENESIS; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DYSPLASIA; HYPERPLASIA; MALE; MOUTH CARCINOMA; NONHUMAN; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; SYRIAN HAMSTER;

9,10-DIMETHYL-1,2-BENZANTHRACENE; ANIMALS; ARACHIDONATE 5-LIPOXYGENASE; CARCINOGENS; CARCINOMA, SQUAMOUS CELL; CELL TRANSFORMATION, NEOPLASTIC; CHEEK; CRICETINAE; DINOPROSTONE; HUMANS; MALE; MOUTH MUCOSA; MOUTH NEOPLASMS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2;

EID: 46149096039     PISSN: 13688375     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2007.08.006     Document Type: Article

References (34)

1. Magrath I., and Litvak J. Cancer in developing countries: opportunity and challenge. J Natl Cancer Inst 85 (1993) 862-874
2. Jemal A., Siegel R., Ward E., et al. Cancer Statistics, 2007. CA Cancer J Clin 57 (2007) 43-66
3. Funk G.F., Karnell L.H., Robinson R.A., et al. Presentation, treatment, and outcome of oral cavity cancer: a National Cancer Data Base report. Head Neck 24 (2002) 165-180
4. Sebastian S., Settleman J., Reshkin S.J., et al. The complexity of targeting EGFR signalling in cancer: from expression to turnover. Biochim Biophys Acta 1766 (2006) 120-139
5. Grandis J.R., and Sok J.C. Signaling through the epidermal growth factor receptor during the development of malignancy. Pharmacol Ther 102 (2004) 37-46
6. Nicholas M.K., Lukas R.V., Jafri N.F., Faoro L., and Salgia R. Epidermal growth factor receptor - mediated signal transduction in the development and therapy of gliomas. Clin Cancer Res 12 (2006) 7261-7270
7. Ono M., and Kuwano M. Molecular mechanisms of epidermal growth factor receptor (EGFR) activation and response to gefitinib and other EGFR-targeting drugs. Clin Cancer Res 12 (2006) 7242-7251
8. Li N., Han C., and Chen J. Tea preparations protect against DMBA-induced oral carcinogenesis in hamsters. Nutr Cancer 35 (1999) 73-79
9. Wong D.T., Gallagher G.T., Gertz R., Chang A.L., and Shklar G. Transforming growth factor alpha in chemically transformed hamster oral keratinocytes. Cancer Res 48 (1988) 3130-3134
10. Shin D.M., Gimenez I.B., Lee J.S., et al. Expression of epidermal growth factor receptor, polyamine levels, ornithine decarboxylase activity, micronuclei, and transglutaminase I in a 7,12-dimethylbenz(a)anthracene-induced hamster buccal pouch carcinogenesis model. Cancer Res 50 (1990) 2505-2510
11. Khan A.J., King B.L., Smith B.D., et al. Characterization of the HER-2/neu oncogene by immunohistochemical and fluorescence in situ hybridization analysis in oral and oropharyngeal squamous cell carcinoma. Clin Cancer Res 8 (2002) 540-548
12. Werkmeister R., Brandt B., and Joos U. Clinical relevance of ErbB-1 and -2 oncogenes in oral carcinomas. Oral Oncol 36 (2000) 100-105
13. Xia W., Lau Y.K., Zhang H.Z., et al. Combination of EGFR, HER-2/neu, and HER-3 is a stronger predictor for the outcome of oral squamous cell carcinoma than any individual family members. Clin Cancer Res 5 (1999) 4164-4174
14. Bei R., Pompa G., Vitolo D., et al. Co-localization of multiple ErbB receptors in stratified epithelium of oral squamous cell carcinoma. J Pathol 195 (2001) 343-348
15. Berta G.N., Mognetti B., Spadaro M., et al. Anti-HER-2 DNA vaccine protects Syrian hamsters against squamous cell carcinomas. Br J Cancer 93 (2005) 1250-1256
16. Reid A., Vidal L., Shaw H., and de Bono J. Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu). Eur J Cancer 43 (2007) 481-489
17. el-Hakim I.E., and Langdon J.D. Arachidonic acid cascade and oral squamous cell carcinoma. Clin Otolaryngol Allied Sci 16 (1991) 563-573
18. Li N., Sood S., Wang S., et al. Overexpression of 5-lipoxygenase and cyclooxygenase 2 in hamster and human oral cancer and chemopreventive effects of zileuton and celecoxib. Clin Cancer Res 11 (2005) 2089-2096
19. Bogatcheva N.V., Sergeeva M.G., Dudek S.M., and Verin A.D. Arachidonic acid cascade in endothelial pathobiology. Microvasc Res 69 (2005) 107-127
20. Claria J., and Romano M. Pharmacological intervention of cyclooxygenase-2 and 5-lipoxygenase pathways. Impact on inflammation and cancer. Curr Pharm Des 11 (2005) 3431-3447
21. Sun Z., Sood S., Li N., et al. Involvement of the 5-lipoxygenase/leukotriene A4 hydrolase pathway in 7,12-dimethylbenz[a]anthracene (DMBA)-induced oral carcinogenesis in hamster cheek pouch, and inhibition of carcinogenesis by its inhibitors. Carcinogenesis 27 (2006) 1902-1908
22. Dannenberg A.J., Lippman S.M., Mann J.R., Subbaramaiah K., and DuBois R.N. Cyclooxygenase-2 and epidermal growth factor receptor: pharmacologic targets for chemoprevention. J Clin Oncol 23 (2005) 254-266
23. Coffey R.J., Hawkey C.J., Damstrup L., et al. Epidermal growth factor receptor activation induces nuclear targeting of cyclooxygenase-2, basolateral release of prostaglandins, and mitogenesis in polarizing colon cancer cells. Proc Natl Acad Sci USA 94 (1997) 657-662
24. Vadlamudi R., Mandal M., Adam L., et al. Regulation of cyclooxygenase-2 pathway by HER2 receptor. Oncogene 18 (1999) 305-314
25. Peppelenbosch M.P., Tertoolen L.G., Hage W.J., and de Laat S.W. Epidermal growth factor-induced actin remodeling is regulated by 5-lipoxygenase and cyclooxygenase products. Cell 74 (1993) 565-575
26. Mitchell M.D. Epidermal growth factor actions on arachidonic acid metabolism in human amnion cells. Biochim Biophys Acta 928 (1987) 240-242
27. Kramer I., Lucas R., Pindborg J., and Sobin L. WHO, Collaborating center for oral precancerous lesions: definitions of leukoplakia and related lesions: an aid to studies on oral precancer. Oral Surg Oral Med Oral Pathol 46 (1978) 518-589
28. Leininger I., and KJokinen M. In: Turosov V. (Ed). Pathology of tumors in laboratory animals (1982), IARC, Albany, NY 167-169
29. Kempen E.C., Yang P., Felix E., Madden T., and Newman R.A. Simultaneous quantification of arachidonic acid metabolites in cultured tumor cells using high-performance liquid chromatography/electrospray ionization tandem mass spectrometry. Anal Biochem 297 (2001) 183-190
30. Li N., Chen X., Liao J., et al. Inhibition of 7,12-dimethylbenz[a]anthracene (DMBA)-induced oral carcinogenesis in hamsters by tea and curcumin. Carcinogenesis 23 (2002) 1307-1313
31. Rusnak D.W., Affleck K., Cockerill S.G., et al. The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer. Cancer Res 61 (2001) 7196-7203
32. Witters L.M., Witkoski A., Planas-Silva M.D., et al. Synergistic inhibition of breast cancer cell lines with a dual inhibitor of EGFR-HER-2/neu and a Bcl-2 inhibitor. Oncol Rep 17 (2007) 465-469
33. Kiguchi K., Ruffino L., Kawamoto T., Ajiki T., and Digiovanni J. Chemopreventive and therapeutic efficacy of orally active tyrosine kinase inhibitors in a transgenic mouse model of gallbladder carcinoma. Clin Cancer Res 11 (2005) 5572-5580
34. Mognetti B., Di Carlo F., and Berta G.N. Animal models in oral cancer research. Oral Oncol 42 (2006) 448-460